Bitcoin faced selling pressure near $88,000 as holders who kept their coins for one to two years sold during the recent price rebound. This level is close to the breakeven point for investors who bought Bitcoin six to 12 months ago, around $89,000. These cost-basis levels indicate where groups of investors acquired Bitcoin on average and act as resistance points that may limit further price gains. The $88,000 mark remains a key level to watch for how different holder groups react as Bitcoin attempts to climb higher.
Bitcoin price action is the subject, with Pluang market data providing context. For readers following major cryptocurrencies, 16 rose and 33 fell today among 50 priced assets. EOS gained 8.13% to Rp12.649, AXS declined 4.83% with 94% sell orders, and COTI dropped 4.79% with 75% buy orders. Data is as of Oct 14, 2026 00:03 WIB.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
